Based on these results, a phase III trial has been conducted to assess PFS in platinum-resistant ovarian cancer patients with FRα expression, randomized to Mirvetuximab soravtansine (IMGN853) or standard chemotherapy (FORWARD I trial, NCT02631876). This evidence concerns the gene FOLR1 and ovarian carcinoma.